Key result
Intravenous procainamide facilitated supraventricular tachycardia induction in 6 of 11 patients by shortening the AV node effective refractory period, while inhibiting it in 5 patients by prolonging the retrograde accessory pathway effective refractory period.
Why the study?
Does intravenous procainamide alter the inducibility of supraventricular tachycardia and electrophysiological properties in patients with accessory pathway syndrome?
Observational (n=11)
No
Does intravenous procainamide alter the inducibility of supraventricular tachycardia and electrophysiological properties in patients with accessory pathway syndrome?
Intravenous procainamide can paradoxically facilitate the induction of supraventricular tachycardia in some patients with accessory pathway syndrome due to its anticholinergic effect shortening the AV node refractory period.
Answers are grounded in this paper and cite their sources.
Procainamide may paradoxically facilitate SVT induction in some accessory pathway patients; hypothesis-generating for its dual electrophysiological effects.
[in Japanese]
No takes yet. Share an insight, caveat, or question.
Akiyama et al. (1983) conducted an observational in Accessory pathway syndrome (WPW syndrome) (n=11). Procainamide vs. Baseline (before administration) was evaluated on Effective refractory period of the atrioventricular node (AVNERP) in patients where PSVT provocation was facilitated (Group A) (p=<0.05). Intravenous procainamide facilitated supraventricular tachycardia induction in 6 of 11 patients by shortening the AV node effective refractory period, while inhibiting it in 5 patients by prolonging the retrograde accessory pathway effective refractory period.
Synapse has enriched 10 related papers. Consider them for comparative context: